Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Post-transplant lymphoproliferative disorder presenting as multiple myeloma.

Ninan MJ, Datta YH.

Am J Hematol. 2010 Aug;85(8):635-7. doi: 10.1002/ajh.21762. Review. No abstract available.

2.

Iatrogenic immunodeficiency-associated lymphoproliferative disease of the Hodgkin lymphoma-like variant in a patient treated with mycophenolate mofetil for autoimmune hepatitis.

Adams B, Lazarchick J, Medina AM, Willner IR, Neville B, Murphy E, Stuart R, Costa LJ.

Am J Hematol. 2010 Aug;85(8):627-9. doi: 10.1002/ajh.21753. No abstract available.

3.

Rituximab therapy and reduction of immunosuppression to rescue graft function after renal posttransplantation lymphoproliferative disorder found by macrohematuria in a pancreas and kidney transplant recipient: a case report.

Miyagi S, Sekiguchi S, Kawagishi N, Akamatsu Y, Satoh K, Takeda I, Fukushima D, Kobayashi Y, Tokodai K, Fujimori K, Satomi S.

Transplant Proc. 2011 Nov;43(9):3299-301. doi: 10.1016/j.transproceed.2011.10.002.

PMID:
22099782
4.

Post-transplantation lymphoproliferative disorder of recipient origin in a boy with acute T-cell leukemia with detection of B-cell clonality 3 months before stem cell transplantation.

Kontny U, Boppana S, Jung A, Goebel H, Strahm B, Peters A, Dormann S, Werner M, Bader P, Fisch P, Niemeyer C.

Haematologica. 2005 Nov;90 Suppl:ECR27.

5.

[Remission of severe disease induced by CMV and lymphoproliferative post-transplant disease after changing the immunosuppressive regime].

Gómez E, Melón S, Fresno MF, Tricas L, Navascués R, de Oña M, Herreros M, Alvarez Grande J.

Nefrologia. 2002;22(6):574-81. Spanish.

6.

Low viral load post-transplant lymphoproliferative disease localized within the tongue.

Henry DD, Hunger SP, Braylan RC, Dharnidharka VR.

Transpl Infect Dis. 2008 Dec;10(6):426-30. doi: 10.1111/j.1399-3062.2008.00328.x. Epub 2008 Jul 22.

PMID:
18657087
7.

Epstein-Barr virus-related lymphoproliferative disorders.

Wagner-Johnston ND, Ambinder RF.

Curr Hematol Malig Rep. 2007 Oct;2(4):249-54. doi: 10.1007/s11899-007-0034-y. Review.

PMID:
20425377
8.

[Virus, immunosuppression, and the kidney transplant recipient].

Alberú J, Villasís A.

Rev Invest Clin. 2005 Jul-Aug;57(4):582-95. Spanish. No abstract available.

PMID:
16315643
9.

Successful treatment with rituximab of an Epstein-Barr virus-associated leiomyosarcoma occurring after liver transplantation.

Jericho H, Weinstein J, Melin-Aldana H, Leuer KC, Wyers M, Alonso EM, Ekong UD.

J Pediatr Gastroenterol Nutr. 2014 Jan;58(1):e2-4. doi: 10.1097/MPG.0b013e31826f2786. No abstract available.

PMID:
24378523
10.

Epstein-Barr virus-driven lymphoproliferative disorder post-CAMPATH-1H (alemtuzumab) in refractory polymyositis.

Cooles FA, Jackson GH, Menon G, Isaacs JD.

Rheumatology (Oxford). 2011 Apr;50(4):810-2. doi: 10.1093/rheumatology/keq429. Epub 2011 Jan 5. No abstract available.

PMID:
21208978
11.

Recurrent posttransplant lymphoproliferative disorder involving the larynx and trachea: case report and review of the literature.

Banks CA, Meier JD, Stallworth CR, White DR.

Ann Otol Rhinol Laryngol. 2012 May;121(5):291-5. Review.

PMID:
22724273
12.

[TAC/MMF/Pred/single shot ATG versus CsA/MMF/Pred single shot ATG after pancreas-/kidney transplantation (PNTX)--initial results of a prospective randomized study].

Schulz T, Heimes M, Schindler A, Büsing M.

Langenbecks Arch Chir Suppl Kongressbd. 1998;115(Suppl I):141-5. German. No abstract available.

PMID:
14518229
13.

Successful treatment of aggressive post transplant lymphoproliferative disorder using rituximab.

O'Dwyer ME, Launder T, Rabkin JM, Nichols CR.

Leuk Lymphoma. 2000 Oct;39(3-4):411-9.

PMID:
11342323
14.

Quiz page. Posttransplantation lymphoproliferative disorder (PTLD) involving the brain and the allograft.

Tang S, Lai KN.

Am J Kidney Dis. 2005 Apr;45(4):A55, e61-2. No abstract available.

PMID:
15806458
15.

[Hematologic malignant complications after transplantation].

Caillard S, Imhoff O, Moulin B.

Nephrol Ther. 2011 Nov;7(6):500-12. doi: 10.1016/j.nephro.2011.03.005. Epub 2011 Apr 30. Review. French.

PMID:
21531185
16.

CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.

Rabot N, Büchler M, Foucher Y, Moreau A, Debiais C, Machet MC, Kessler M, Morelon E, Thierry A, Legendre C, Rivalan J, Kamar N, Dantal J.

Transpl Int. 2014 Sep;27(9):956-65. doi: 10.1111/tri.12375. Epub 2014 Aug 20.

17.

Aggressive posttransplant lymphoproliferative disease in a renal transplant patient treated with alemtuzumab.

Muzaffar M, Taj A, Ratnam S.

Am J Ther. 2010 Nov-Dec;17(6):e230-3. doi: 10.1097/MJT.0b013e3181c08042.

PMID:
19918163
18.

[Association of post-transplant lymphoproliferative disease and visceral leishmaniasis after kidney transplantation].

Bacha MM, Abderrahim E, Ounissi M, Chaouech D, Cherif M, Turki S, Rajhi H, Znaidi N, Bahloul A, Trabelsi S, Khaled S, Ben Abdallah T, Ben Maïz H, Kheder A.

Nephrol Ther. 2011 Nov;7(6):488-93. doi: 10.1016/j.nephro.2011.01.010. Epub 2011 Mar 3. French.

PMID:
21376690
19.
20.

Supplemental Content

Support Center